Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants (non-childbearing potential), with a body mass index (BMI) between 18 to 35 kilogram per square meter (kg/m\^2) (All participants).~2. Participants with hepatic impairment who are medically stable as determined by the investigator, based on medical history and clinical evaluations including physical examinations, clinical laboratory tests, vital sign measurements, and 12-lead ECGs performed at the Screening Visit and at check-in on Day -1 (Group 1 to 3).~3. Healthy participants (Group 4).~Exclusion Criteria:~Participants who have:~1. A history of hepatic carcinoma, hepatorenal syndrome, or presence of a liver mass by ultrasound, CT or MRI, or acute liver disease caused by an infection or drug toxicity (Group 1 to 3).~2. Have severe hepatic encephalopathy (\[greater than\] \> Grade II Portal Systemic Encephalopathy Score) (Group 1 to 3).~3. Surgical porto-systemic shunts, including transjugular intrahepatic portosystemic shunt (Group 1 to 3).~4. A history of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to trial entry (Group 1 to 3).~5. Bilirubin levels above 5 times the upper limit of normal (ULN) at screening or Day -1 for Groups 1 and 2, there is no limit for Group 3.~6. Severe/advanced ascites and/or pleural effusion which requires emptying and albumin supplementation, as judged by the investigator (Group 1 to 3).~7. Renal creatinine clearance (CLcr) less than or equal to (\<=) 50 milliliter per minute (mL/min), calculated using the Cockcroft-Gault equation from the serum creatinine measurement taken at screening (Group 1 to 3).~8. Who have a history of clinically significant endocrine, gastrointestinal (GI) (including motility disorder and intestinal obstruction), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial (Group 4).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg (Type: EXPERIMENTAL): TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
- Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg (Type: EXPERIMENTAL): TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
- Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg (Type: EXPERIMENTAL): TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
- Group 4 Healthy Participants: TAK-954 0.2 mg (Type: EXPERIMENTAL): TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete